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Biology

In Vitro and In Silico Evaluation of Novel
Ortho-Substituted Phenols and Benzodiazepine
Derivatives as Potent and Isoform-Specific
Human and Schistosoma mansoni Lysine
Deacetylase Inhibitors
Rong Hu
Mentors: Flavio Ballante and Garland R. Marshall
The study of epigenetics, or heritable changes in gene expression without genomic
alterations, has been rapidly expanding due to the discovery of critical epigenetic
contributions involved in human diseases. One such epigenetic mechanism is the
reversible acetylation of lysine ε-amino groups, a post-translational modification that
often occurs on histone tails to regulate transcription. Responsible for catalyzing acetyl
group removal, the lysine deacetylase (KDAC) family of enzymes has been found to be
linked with the development/progression of cancer, diabetes, and other critical disorders
in humans when aberrant expression, activity, or mutations are present. KDACs also
contribute to various parasitic diseases, including schistosomiasis, a disease concerning
the infection of human intestinal and urogenital tracts by Schistosoma trematodes.
Thus, development of potent KDAC inhibitors (KDACIs) against specific human and
parasitic KDAC isoforms may lead to innovative therapies for many diseases.
In this study, we focus on the screening of novel KDACIs against four human
KDAC isozymes (hKDAC1, 3, 6, and 8) and one Schistosoma mansoni KDAC isozyme
(smKDAC8) using in vitro and in silico methods. Synthesized phenol and
benzodiazepine derivatives were tested as inhibitors against each KDAC isozyme using
electrophoretic mobility shift assays to measure relative half maximal inhibitory
concentrations (IC50s).
Experimental results revealed several KDACIs endowed with low nanomolar IC50s
and high selectivity against hKDAC6, as well as KDACIs with mid-range nanomolar
IC50s and selectivity against hKDAC3. Structure-activity relationships (SARs) were then
rationalized through molecular docking simulations, further clarifying ligand-residue
interactions relevant to inhibitory potency and isoform-selectivity against human and
schistosome KDACs. The obtained data will be used to (1) refine a comprehensive
pharmacophore model (recently published by the Marshall lab); (2) design and
synthetize novel KDACIs with higher potency and selectivity; and (3) enhance
structure-based 3D QSAR models as tools to predict the activity/selectivity of
novel/untested compounds through virtual screening applications.
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